News: Portfolio 2009

CELLUMEN APPOINTS DR. JACK A. REYNOLDS TO BOARD OF DIRECTORS

Pharmaceutical industry veteran brings more than 30 years of experience to Cellumen

Pittsburgh, PA, March 26, 2009 – Cellumen, Inc., a discovery toxicology company, today announced that industry veteran and former Pfizer executive Dr. Jack A. Reynolds has joined Cellumen’s board of directors. With more than 30 years of experience in the pharmaceutical industry, Dr. Reynolds is founder and Principal at JAReynolds & Associates, which is focused on defining new paradigms for improving safety testing and decision making in the pharmaceutical industry.

 

“We are incredibly pleased to welcome Jack to our team,” says D. Lansing Taylor, Ph.D., CEO of Cellumen. “He is highly regarded for his work in early safety testing, and we are confident that he will serve as a trusted advisor for the team at Cellumen, helping us to continue identifying safety liabilities earlier in the drug development process.” Prior to his current role, Dr. Reynolds worked at Pfizer Global Research and Development